In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea

Hwa Yum Jong, Ki Kim Chang, Dongeun Yong, Kyungwon Lee, Yunsop Chong, Min Kim Cheol, Mi Kim Jeong, Seonggu Ro, Myung Cho Joong

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC90 of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.

Original languageEnglish
Pages (from-to)2591-2593
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume51
Issue number7
DOIs
Publication statusPublished - 2007 Jul 1

Fingerprint

Linezolid
Korea
Vancomycin
Staphylococcus aureus
CG 400549
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Jong, Hwa Yum ; Chang, Ki Kim ; Yong, Dongeun ; Lee, Kyungwon ; Chong, Yunsop ; Cheol, Min Kim ; Jeong, Mi Kim ; Ro, Seonggu ; Joong, Myung Cho. / In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. In: Antimicrobial agents and chemotherapy. 2007 ; Vol. 51, No. 7. pp. 2591-2593.
@article{debaf7696c31458dba69a73b46642bba,
title = "In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea",
abstract = "The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC90 of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.",
author = "Jong, {Hwa Yum} and Chang, {Ki Kim} and Dongeun Yong and Kyungwon Lee and Yunsop Chong and Cheol, {Min Kim} and Jeong, {Mi Kim} and Seonggu Ro and Joong, {Myung Cho}",
year = "2007",
month = "7",
day = "1",
doi = "10.1128/AAC.01562-06",
language = "English",
volume = "51",
pages = "2591--2593",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. / Jong, Hwa Yum; Chang, Ki Kim; Yong, Dongeun; Lee, Kyungwon; Chong, Yunsop; Cheol, Min Kim; Jeong, Mi Kim; Ro, Seonggu; Joong, Myung Cho.

In: Antimicrobial agents and chemotherapy, Vol. 51, No. 7, 01.07.2007, p. 2591-2593.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea

AU - Jong, Hwa Yum

AU - Chang, Ki Kim

AU - Yong, Dongeun

AU - Lee, Kyungwon

AU - Chong, Yunsop

AU - Cheol, Min Kim

AU - Jeong, Mi Kim

AU - Ro, Seonggu

AU - Joong, Myung Cho

PY - 2007/7/1

Y1 - 2007/7/1

N2 - The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC90 of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.

AB - The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC90 of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.

UR - http://www.scopus.com/inward/record.url?scp=34447263022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447263022&partnerID=8YFLogxK

U2 - 10.1128/AAC.01562-06

DO - 10.1128/AAC.01562-06

M3 - Article

C2 - 17420210

AN - SCOPUS:34447263022

VL - 51

SP - 2591

EP - 2593

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -